Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBITDA (2020 - 2025)

Cytek Biosciences' EBITDA history spans 6 years, with the latest figure at -$42.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 546.32% year-over-year to -$42.7 million; the TTM value through Dec 2025 reached -$64.3 million, down 1259.99%, while the annual FY2025 figure was -$64.3 million, 1259.7% down from the prior year.
  • EBITDA reached -$42.7 million in Q4 2025 per CTKB's latest filing, down from -$4.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $9.6 million in Q4 2024 to a low of -$42.7 million in Q4 2025.
  • Average EBITDA over 5 years is -$3.6 million, with a median of -$1.6 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 169.63% in 2022, then plummeted 823.04% in 2023.
  • A 5-year view of EBITDA shows it stood at $1.3 million in 2021, then soared by 169.63% to $3.6 million in 2022, then soared by 63.53% to $5.8 million in 2023, then soared by 64.58% to $9.6 million in 2024, then crashed by 546.32% to -$42.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's EBITDA are -$42.7 million (Q4 2025), -$4.6 million (Q3 2025), and -$5.0 million (Q2 2025).